Halofuginone, a promising drug for treatment of pulmonary hypertension
British Journal of Pharmacology2021Vol. 178(17), pp. 3373–3394
Citations Over TimeTop 10% of 2021 papers
Pritesh Jain, Tengteng Zhao, Mingmei Xiong, Shanshan Song, Ning Lai, Qiuyu Zheng, Jiyuan Chen, Shane G. Carr, Aleksandra Babicheva, Amin Izadi, Marisela Rodriguez, Shamin Rahimi, Francesca Balistrieri, Shayan Rahimi, Tatum S. Simonson, Daniela Valdez‐Jasso, Patricia A. Thistlethwaite, John Y.‐J. Shyy, Jian Wang, Ayako Makino, Jason X.‐J. Yuan
Abstract
Halofuginone is a potent pulmonary vasodilator by activating Kv channels and blocking VDCC and receptor-operated and store-operated Ca2+ channels in PASMCs. The therapeutic effect of halofuginone on experimental PH is probably due to combination of its vasodilator effects, via inhibition of excitation-contraction coupling and anti-proliferative effects, via inhibition of the PI3K/Akt/mTOR signalling pathway.
Related Papers
- → Growth hormone binding protein in the rat: effects of gonadal steroids.(1993)59 cited
- → Exogenous Glucocorticoids and a High-Fat Diet Cause Severe Hyperglycemia and Hyperinsulinemia and Limit Islet Glucose Responsiveness in Young Male Sprague-Dawley Rats(2013)47 cited
- → The Effect of Fasting on Tissue Cyclic cAMP and Plasma Glucagon in the Obese Hyperglycemic Mouse(1975)39 cited
- → Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide(2004)39 cited
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)